| Dec'17 | ||||||
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net income before tax expense | ||||||
1,647 | ||||||
Reconciliation of net income before taxes and net cash provided by operating activities: | ||||||
Depreciation of tangible assets | ||||||
155 | ||||||
Amortization of intangible assets | ||||||
146 | ||||||
Impairment losses of loans and receivables | ||||||
1,387 | ||||||
Net interest income | ||||||
3,523 | ||||||
Gains in non-monetary transactions | ||||||
0 | ||||||
Impairment of investments, net | ||||||
47 | ||||||
Effect for change in accounting polices | ||||||
0 | ||||||
(Gains) losses on sales of non-current assets held for sale | ||||||
-2 | ||||||
Gains on available for sale financial assets | ||||||
-17 | ||||||
Writedown in concessions | ||||||
1 | ||||||
Recovery of impairment loss on tangible assets | ||||||
1 | ||||||
Foreign exchange (gains) losses | ||||||
-33 | ||||||
Share of undistributed profit of equity accounted investees, net of tax | ||||||
57 | ||||||
Interest accrual of issued bonds outstanding | ||||||
1 | ||||||
Fair value adjustments to: | ||||||
Derivative financial instruments | ||||||
55 | ||||||
Financial asset at fair value through profit or losses | ||||||
-3 | ||||||
Investment property | ||||||
15 | ||||||
Biological assets | ||||||
4 | ||||||
Changes in operating assets and liabilities: | ||||||
Decrease in financial assets held for trading | ||||||
706 | ||||||
Increase in other accounts receivable | ||||||
-269 | ||||||
Decrease in non-current assets held for sale | ||||||
5 | ||||||
Increase (decrease) in derivative financial instruments | ||||||
16 | ||||||
Increase (decrease) in other assets | ||||||
42 | ||||||
Decrease (increase) in other liabilities and provisions | ||||||
93 | ||||||
Increase in employee benefits | ||||||
15 | ||||||
(Increase) in loans and receivables | ||||||
-4,860 | ||||||
Increase in customer deposits | ||||||
3,840 | ||||||
(Decrease) increase in interbank borrowings and overnight funds | ||||||
-489 | ||||||
(Decrease) in borrowings from development entities | ||||||
-0 | ||||||
Increase of borrowings from banks and others | ||||||
172 | ||||||
Interest received | ||||||
6,074 | ||||||
Interest paid | ||||||
2,790 | ||||||
Income tax, wealth tax and equity tax payments | ||||||
527 | ||||||
Net cash provided by operating activities | ||||||
1,712 | ||||||
Cash flows from investing activities: | ||||||
Acquisition of property plant and equipment | ||||||
158 | ||||||
Acquisition of investment property | ||||||
25 | ||||||
Additions to biological assets | ||||||
8 | ||||||
Additions to investments in associates and joint ventures | ||||||
0 | ||||||
Additions of concession arrangement right | ||||||
204 | ||||||
Additions of other intangible assets | ||||||
90 | ||||||
(Increase) decrease in available for sale financial assets | ||||||
-747 | ||||||
Proceeds from sales of property and equipment | ||||||
23 | ||||||
Proceeds from sales of investment properties | ||||||
9 | ||||||
Proceeds from sales of biological assets | ||||||
6 | ||||||
Proceeds from sales of non-current assets held for sale | ||||||
28 | ||||||
Proceeds from sale of investments in associates and joint ventures | ||||||
0 | ||||||
Purchases of held-to-maturity financial assets | ||||||
1,241 | ||||||
Maturities of held-to-maturity financial assets | ||||||
1,127 | ||||||
Dividends received from investments | ||||||
57 | ||||||
Business combination, net of cash | ||||||
13 | ||||||
Net cash used in investing activities | ||||||
-1,210 | ||||||
Cash flows from financing activities: | ||||||
Dividends paid to shareholders | ||||||
438 | ||||||
Issuance of debt securities | ||||||
1,524 | ||||||
Payment of outstanding debt securities | ||||||
1,311 | ||||||
Issuance of common shares | ||||||
0 | ||||||
Acquisition of non controlling interest | ||||||
1 | ||||||
Dividends paid to non-controlling interest | ||||||
257 | ||||||
Net cash provided by (used in) financing activities | ||||||
-484 | ||||||
Effect of foreign currency changes on cash and cash equivalents | ||||||
30 | ||||||
Increase (decrease) in cash and cash equivalents | ||||||
48 | ||||||